EUVIMEDEUVIMED entdecken
Open Access

Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy

Sarah C J Jorgensen, Samantha S M Drover, Deshayne B Fell, Peter C Austin, Rohan D'Souza, Astrid Guttmann, Sarah A Buchan, Sarah E Wilson, Sharifa Nasreen, Kevin L Schwartz, Mina Tadrous, Kumanan Wilson und 1 weitere

JAMA Pediatrics · 01.12.2023 · 177 (12) · 1314

DOI: 10.1001/jamapediatrics.2023.4499 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Pediatrics, erschienen am 01.12.2023. Verfasst von Sarah C J Jorgensen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Perinatal Death, COVID-19. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CIHR.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The study team previously showed that maternal mRNA COVID-19 vaccination during pregnancy confers protection against SARS-CoV-2 infection and COVID-19–related hospital admission in newborns and young infants. In this study, the study team evaluated newborn and early infant safety outcomes following maternal messenger RNA (mRNA) COVID-19 vaccination during pregnancy, for which there is limited comparative epidemiological evidence.

Objective

To determine if maternal mRNA COVID-19 vaccination during pregnancy is associated with adverse newborn and early infant outcomes. Design, Setting, and Participants This population-based retrospective cohort study took place in Ontario, Canada, using multiple linked health administrative databases. Singleton live births with an expected delivery date between May 1, 2021, and September 2, 2022, were included. Data were analyzed from January 2023 through March 2023. Exposure Maternal mRNA COVID-19 vaccination (1 or more doses) during pregnancy Main Outcomes and Measures Severe neonatal morbidity (SNM), neonatal death, neonatal intensive care unit (NICU) admission, neonatal readmission, and hospital admission up to 6 months of age. The study team calculated inverse probability of treatment weighted risk ratios (RRs) and fit weighted Cox proportional hazards regression models comparing outcomes in infants of mothers who received COVID-19 vaccination during pregnancy with those who received no COVID-19 vaccine doses before delivery.

Results

In total, 142 006 infants (72 595 male [51%]; mean [SD] gestational age at birth, 38.7 [1.7] weeks) were included; 85 670 were exposed to 1 or more COVID-19 vaccine doses in utero (60%). Infants of vaccinated mothers had lower risks of SNM (vaccine exposed 7.3% vs vaccine unexposed 8.3%; adjusted RR [aRR], 0.86; 95% CI, 0.83-0.90), neonatal death (0.09% vs 0.16%; aRR, 0.47; 95% CI, 0.33-0.65), and NICU admission (11.4% vs 13.1%; aRR, 0.86; 95% CI, 0.83-0.89). There was no association between maternal vaccination during pregnancy and neonatal readmission (5.5% vs 5.1%; adjusted hazard ratio, 1.03; 95% CI, 0.98-1.09) or 6-month hospital admission (8.4% vs 8.1%; adjusted hazard ratio, 1.01; 95% CI, 0.96-1.05). Conclusions and Relevance In this population-based cohort study in Ontario, Canada, maternal mRNA COVID-19 vaccination during pregnancy was associated with lower risks of SNM, neonatal death, and NICU admission. In addition, neonatal and 6-month readmissions were not increased in infants of mothers vaccinated during pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Perinatal DeathCOVID-19PregnancyFemaleInfantInfant, NewbornMaleHumansRetrospective StudiesCOVID-19 VaccinesCohort StudiesRNA, Messenger, StoredSARS-CoV-2OntarioVaccination

Substanzen

COVID-19 VaccinesRNA, Messenger, Stored

Autor:innen und Institutionen

  • Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
  • ICES, Toronto, Ontario, Canada.
  • School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.
  • Children's Hospital of Eastern Ontario Research Institute, Ottawa, Ontario, Canada.
  • Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.
  • Departments of Obstetrics and Gynecology and Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.

Förderung

  • CIHR

Zitieren

APA

Jorgensen, S. C. J., Drover, S. S. M., Fell, D. B., Austin, P. C., D'Souza, R., Guttmann, A., Buchan, S. A., Wilson, S. E., Nasreen, S., Schwartz, K. L., Tadrous, M., Wilson, K., & Kwong, J. C. (2023). Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy. JAMA Pediatrics, 177(12), 1314. https://doi.org/10.1001/jamapediatrics.2023.4499

Vancouver

Jorgensen SCJ, Drover SSM, Fell DB, Austin PC, D'Souza R, Guttmann A, et al. Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy. JAMA Pediatrics. 2023;177(12):1314. doi:10.1001/jamapediatrics.2023.4499

BibTeX
@article{Jorgensen2023,
  author = {Jorgensen, Sarah C J and Drover, Samantha S M and Fell, Deshayne B and Austin, Peter C and D'Souza, Rohan and Guttmann, Astrid and Buchan, Sarah A and Wilson, Sarah E and Nasreen, Sharifa and Schwartz, Kevin L and Tadrous, Mina and Wilson, Kumanan and Kwong, Jeffrey C},
  title = {Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy},
  journal = {JAMA Pediatrics},
  year = {2023},
  volume = {177},
  number = {12},
  pages = {1314},
  doi = {10.1001/jamapediatrics.2023.4499}
}
Kostenlos starten →